OmniScience and INmune Bio (INMB) announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease clinical trial using OmniScience’s flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents a innovative approach to clinical research, delivering immediate insights that enhance decision-making and transform traditional, time-consuming trial management. INmune and OmniScience partnered throughout Vivo’s product development and have completed the first phase of Vivo’s roll-out to INmune’s clinical development team. Throughout the initial rollout, significant beneficial findings include: Improved data quality through Vivo’s automatic identification of data discrepancies; Enhanced visualization of COAs, supporting identification of outliers and better understanding of population distributions; Real-time answers, supporting decisions on patient enrollment criteria, even while the patient is in the clinic; Reduced reliance on time-consuming spreadsheet-based data analysis, improving collaboration between clinical and executive teams.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.